Background: The Vagus Nerve and Autonomic Regulation
The vagus nerve — the tenth cranial nerve and the longest in the body — serves as the primary conduit of the parasympathetic nervous system, innervating the heart, lungs, and gastrointestinal tract. Its tone, commonly indexed through heart rate variability (HRV), has become a significant biomarker of autonomic nervous system function, resilience to stress, and broader physiological health.
Higher vagal tone, reflected by greater HRV, has been consistently associated in observational research with reduced cardiovascular risk, improved emotional regulation, better immune function, and lower rates of anxiety and depression.1,2 This body of evidence has generated considerable interest in the possibility of deliberately enhancing vagal tone through targeted interventions — and has directly fuelled the emergence of a consumer wearable market making exactly that claim.
The clinical question is a legitimate one: can external stimulation or biofeedback devices meaningfully and durably increase vagal tone? And if so, under what conditions, in which populations, and with what magnitude of effect? This review examines the current evidence base critically and without commercial bias.
HRV is widely used as a proxy measure for vagal tone, though the relationship is not perfectly linear. Higher resting HRV broadly reflects greater parasympathetic dominance, but HRV is influenced by multiple factors including age, fitness, sleep quality, respiratory rate, and medication — all of which must be controlled for in research and clinical interpretation.
Categories of Vagal Tone Devices
Consumer and clinical devices targeting the vagus nerve fall into two mechanistically distinct categories: transcutaneous vagus nerve stimulation (tVNS) devices, which apply a mild electrical current to the auricular branch of the vagus nerve at the ear, and HRV biofeedback devices, which use real-time physiological feedback to guide slow-paced breathing protocols known to acutely increase HRV.
1. Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
taVNS applies low-intensity electrical stimulation to the cymba conchae of the ear, a site where the auricular branch of the vagus nerve is accessible through the skin. Unlike invasive cervical VNS — an established therapy for epilepsy and treatment-resistant depression — taVNS is non-invasive and has attracted substantial research interest as a lower-risk alternative.
A 2021 randomised controlled trial published in Aging by Bretherton et al. found that daily taVNS applied for two weeks in healthy older adults produced a statistically significant increase in HRV and a reduction in sympathovagal balance compared to sham stimulation.3 Participants aged 55 and over showed the most pronounced response, which the authors attributed to greater baseline sympathetic dominance in older populations — a finding with plausible biological rationale.
A 2023 systematic review and meta-analysis in Brain Stimulation (Yap et al.) examined 28 RCTs of taVNS across varied clinical populations and found a pooled moderate positive effect on HRV metrics, with the strongest effects seen in populations with documented autonomic dysfunction — including post-COVID autonomic disorders, heart failure, and inflammatory conditions.4 In healthy younger populations, effects were smaller and less consistent.
The majority of taVNS trials are short in duration (2–8 weeks), use varying stimulation parameters (frequency, intensity, pulse width), and employ heterogeneous HRV outcome measures. Direct comparison across studies is therefore difficult. No large-scale long-term RCT has yet established whether acute HRV improvements translate into durable clinical outcomes in healthy populations.
2. HRV Biofeedback Devices
HRV biofeedback devices — including the Inner Balance by HeartMath, Heartrate+ Coherence Pro, and several app-based systems — use photoplethysmography (PPG) sensors to measure heart rate in real time and guide users through slow, paced breathing, typically at a resonance frequency of approximately 0.1 Hz (roughly 5–7 breaths per minute). At this frequency, respiration and heart rate oscillations enter a state of coherence that maximises acute HRV amplitude.
A 2017 meta-analysis by Goessl et al. in Psychological Medicine pooled 24 studies of HRV biofeedback and found a large effect size (Hedges' g = 0.83) for reduction in self-reported anxiety and a moderate effect (g = 0.52) for HRV improvement at rest.5 Importantly, these benefits were most robust in clinical populations with anxiety disorders, and the majority of gains were maintained at follow-up assessments.
A subsequent systematic review by Wheat and Larkin (2020) in Frontiers in Psychology highlighted that paced breathing alone — without biofeedback technology — produces comparable acute HRV increases in many studies, raising the question of whether the device hardware provides measurable additive benefit over and above the breathing technique itself.6
The biofeedback element may be most valuable for patient adherence and real-time guidance rather than representing a mechanistically essential component. Patients who find unassisted slow breathing difficult to sustain may benefit most from device-guided protocols.
Key Consumer Devices: A Balanced Assessment
| Device | Mechanism | Strength of Evidence | Notable Limitations |
|---|---|---|---|
| NuCalm | Neuroacoustic stimulation + biosignal disc claimed to inhibit adrenaline | Weak. Limited peer-reviewed RCT data. Primarily proprietary research. | Mechanism of biosignal disc is implausible by current biophysics. No independent replication of core claims. |
| HeartMath Inner Balance | HRV biofeedback via PPG sensor guiding paced breathing | Moderate. Supported by independent RCTs for anxiety, stress, and HRV coherence. | Most robust evidence is for anxiety; gains in resting HRV less consistently demonstrated outside sessions. |
| Sensate | Infrasonic vibration to sternum, claimed to activate vagal pathways | Insufficient. One small industry-funded study. No independent peer-reviewed RCTs at time of writing. | No established mechanism for infrasonic sternal vibration activating vagal afferents. Requires independent validation. |
| Pulsetto | Transcutaneous auricular VNS (taVNS) | Plausible mechanism; limited device-specific data. General taVNS literature is more substantive. | Device-specific RCTs lacking. Stimulation parameters vary from research-grade devices used in published trials. |
| Apollo Neuro | Vibrotactile stimulation to wrist or ankle, claimed to modulate autonomic tone | Limited. One pilot RCT (Ramasubramanian et al., 2022) showed modest HRV improvement. Larger independent trials needed. | Mechanism speculative. Effect sizes small. Industry-affiliated research. |
| Garmin / Apple Watch HRV tracking | Passive HRV monitoring (not stimulation) | Reasonable accuracy for trend tracking when used consistently; not a therapeutic device. | Single-point measurements unreliable. Consumer-grade PPG less accurate than chest ECG, particularly during movement. |
What the Evidence Supports — and What It Does Not
The most defensible conclusions from the current literature are as follows. Paced slow breathing at resonance frequency (approximately 5–7 breaths per minute) reliably and acutely increases HRV. This effect is well-established, mechanistically understood, and does not require a wearable device to achieve. Biofeedback devices can assist patients in achieving and sustaining this breathing pattern, which may improve adherence and clinical outcomes in anxious or dysregulated populations.
taVNS, particularly applied to the auricular branch at the cymba conchae, shows genuine mechanistic plausibility and emerging evidence of HRV benefit — especially in older adults and those with baseline autonomic dysfunction. However, the optimal stimulation parameters remain undefined, and consumer devices have not been tested against the protocols used in published research trials.
For the majority of consumer devices making vagal tone claims — particularly those based on vibration, infrasound, or proprietary biosignal technologies — the evidence base is either industry-funded, methodologically weak, or absent. This does not mean the devices are ineffective; it means the claim of efficacy is currently unsupported by independent science.
A core limitation across this field is that HRV as measured during or immediately after a device session reflects an acute respiratory-driven phenomenon — not necessarily an improvement in resting autonomic set-point. Demonstrating genuine upward shift in tonic vagal tone requires measurements taken at rest, across multiple time points, with controlled breathing rates. Very few consumer device studies meet this standard.
Populations Most Likely to Benefit
The evidence is strongest for clinical benefit in populations with documented autonomic dysregulation, including post-COVID autonomic dysfunction, heart failure with reduced ejection fraction, treatment-resistant depression and anxiety disorders, and chronic inflammatory conditions with elevated sympathetic tone. In these contexts, adjunctive use of validated HRV biofeedback or taVNS protocols may represent a clinically meaningful intervention.
In healthy, well-regulated individuals, the marginal benefit of wearable vagal tone devices over and above established lifestyle interventions — aerobic exercise, adequate sleep, diaphragmatic breathing, cold exposure, and social connection — is not currently established by the evidence and should not be assumed.
Clinical Recommendations for Practitioners
For practitioners considering recommending vagal tone devices, a measured approach is warranted. The foundation of vagal tone improvement in any patient remains lifestyle-based: regular aerobic exercise has the most consistent and durable HRV-improving evidence of any intervention.7 Slow diaphragmatic breathing practice, even without a device, is low-cost, safe, and supported by robust data.
Where a device is considered, HRV biofeedback systems with an independent evidence base — such as HeartMath — are preferable to those relying solely on proprietary or industry-funded research. For patients with documented autonomic dysfunction, taVNS represents a reasonable adjunct to explore, ideally within a structured protocol guided by a practitioner familiar with the literature.
Practitioners should be candid with patients that the consumer vagal tone wearable market is substantially ahead of its evidence base. Many devices are safe and may offer benefit through relaxation, engagement, and structured breathing practice — but the specific mechanisms claimed by manufacturers frequently outpace what the science currently supports.
The most evidence-supported approach to improving vagal tone remains aerobic exercise, consistent slow-paced breathing practice, quality sleep, and stress reduction. HRV biofeedback devices with independent research support may be a useful adjunct, particularly in clinical populations. Most other consumer vagal tone wearables require considerably more independent research before strong recommendations can be made.
